TY - JOUR
T1 - Findings from the Adjuvant Colon Cancer End Points (ACCENT) Collaborative Group
T2 - The power of pooled individual patient data from multiple clinical trials
AU - Renfro, Lindsay A.
AU - Sargent, Daniel J.
N1 - Publisher Copyright:
© Chinese Clinical Oncology. All rights reserved.
PY - 2016
Y1 - 2016
N2 - The Adjuvant Colon Cancer End Points (ACCENT) Collaborative Group was formed 15 years ago to address scientific questions in early stage colon cancer that could best be answered by pooling individual patient data across many randomized clinical trials. Today, the ACCENT database contains detailed information collected from over 40,000 patients enrolled onto 27 major adjuvant colon cancer trials conducted between 1977 and 2009. Since its inception, the ACCENT group has led many sophisticated analyses addressing a variety of clinical questions, such as the long-term survivorship of colon cancer patients by treatment, the time course of oxaliplatin benefit, and support for the use of disease-free survival (DFS) as a surrogate endpoint for overall survival (OS), among many others. Here, we provide an updated overview of recent important results and future directions of the ACCENT collaboration.
AB - The Adjuvant Colon Cancer End Points (ACCENT) Collaborative Group was formed 15 years ago to address scientific questions in early stage colon cancer that could best be answered by pooling individual patient data across many randomized clinical trials. Today, the ACCENT database contains detailed information collected from over 40,000 patients enrolled onto 27 major adjuvant colon cancer trials conducted between 1977 and 2009. Since its inception, the ACCENT group has led many sophisticated analyses addressing a variety of clinical questions, such as the long-term survivorship of colon cancer patients by treatment, the time course of oxaliplatin benefit, and support for the use of disease-free survival (DFS) as a surrogate endpoint for overall survival (OS), among many others. Here, we provide an updated overview of recent important results and future directions of the ACCENT collaboration.
KW - Adjuvant Colon Cancer End Points (ACCENT)
KW - Adjuvant treatment
KW - Colon cancer
KW - Disease-free survival (DFS)
KW - FOLFOX
KW - Individual patient data
KW - Meta-analysis
KW - Overall survival (OS)
KW - Oxaliplatin
KW - Population survival; recurrence; surrogate endpoints
UR - http://www.scopus.com/inward/record.url?scp=85010189016&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85010189016&partnerID=8YFLogxK
U2 - 10.21037/cco.2016.12.02
DO - 10.21037/cco.2016.12.02
M3 - Article
C2 - 28061544
AN - SCOPUS:85010189016
SN - 2304-3865
VL - 5
JO - Chinese clinical oncology
JF - Chinese clinical oncology
IS - 6
M1 - 80
ER -